These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 27528549)

  • 21. Chronic administration of Glucagon-like peptide-1 receptor agonists improves trabecular bone mass and architecture in ovariectomised mice.
    Pereira M; Jeyabalan J; Jørgensen CS; Hopkinson M; Al-Jazzar A; Roux JP; Chavassieux P; Orriss IR; Cleasby ME; Chenu C
    Bone; 2015 Dec; 81():459-467. PubMed ID: 26314515
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Repression of osteocyte Wnt/β-catenin signaling is an early event in the progression of renal osteodystrophy.
    Sabbagh Y; Graciolli FG; O'Brien S; Tang W; dos Reis LM; Ryan S; Phillips L; Boulanger J; Song W; Bracken C; Liu S; Ledbetter S; Dechow P; Canziani ME; Carvalho AB; Jorgetti V; Moyses RM; Schiavi SC
    J Bone Miner Res; 2012 Aug; 27(8):1757-72. PubMed ID: 22492547
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Increased PHOSPHO1 expression mediates cortical bone mineral density in renal osteodystrophy.
    Hsu SN; Stephen LA; Dillon S; Milne E; Javaheri B; Pitsillides AA; Novak A; Millán JL; MacRae VE; Staines KA; Farquharson C
    J Endocrinol; 2022 Sep; 254(3):153-167. PubMed ID: 35900032
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Bone Quality in Chronic Kidney Disease: Definitions and Diagnostics.
    McNerny EMB; Nickolas TL
    Curr Osteoporos Rep; 2017 Jun; 15(3):207-213. PubMed ID: 28447312
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Systemic Activation of Activin A Signaling Causes Chronic Kidney Disease-Mineral Bone Disorder.
    Sugatani T
    Int J Mol Sci; 2018 Aug; 19(9):. PubMed ID: 30142896
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Mechanical loading-related changes in osteocyte sclerostin expression in mice are more closely associated with the subsequent osteogenic response than the peak strains engendered.
    Moustafa A; Sugiyama T; Prasad J; Zaman G; Gross TS; Lanyon LE; Price JS
    Osteoporos Int; 2012 Apr; 23(4):1225-34. PubMed ID: 21573880
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Mechanical load increases in bone formation via a sclerostin-independent pathway.
    Morse A; McDonald MM; Kelly NH; Melville KM; Schindeler A; Kramer I; Kneissel M; van der Meulen MC; Little DG
    J Bone Miner Res; 2014 Nov; 29(11):2456-67. PubMed ID: 24821585
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Sclerostin alters serum vitamin D metabolite and fibroblast growth factor 23 concentrations and the urinary excretion of calcium.
    Ryan ZC; Ketha H; McNulty MS; McGee-Lawrence M; Craig TA; Grande JP; Westendorf JJ; Singh RJ; Kumar R
    Proc Natl Acad Sci U S A; 2013 Apr; 110(15):6199-204. PubMed ID: 23530237
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Sclerostin deficiency effectively promotes bone morphogenetic protein-2-induced ectopic bone formation.
    Nakamura K; Koide M; Kobayashi Y; Yamashita T; Matsushita M; Yasuda H; Ishihara Y; Yoshinari N; Udagawa N
    J Periodontal Res; 2023 Aug; 58(4):769-779. PubMed ID: 37154419
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effect of sclerostin-neutralising antibody on periarticular and systemic bone in a murine model of rheumatoid arthritis: a microCT study.
    Marenzana M; Vugler A; Moore A; Robinson M
    Arthritis Res Ther; 2013; 15(5):R125. PubMed ID: 24432364
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Exercise Alleviates Osteoporosis in Rats with Mild Chronic Kidney Disease by Decreasing Sclerostin Production.
    Liao HW; Huang TH; Chang YH; Liou HH; Chou YH; Sue YM; Hung PH; Chang YT; Ho PC; Tsai KJ
    Int J Mol Sci; 2019 Apr; 20(8):. PubMed ID: 31027235
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Mice with sclerostin gene deletion are resistant to the severe sublesional bone loss induced by spinal cord injury.
    Qin W; Zhao W; Li X; Peng Y; Harlow LM; Li J; Qin Y; Pan J; Wu Y; Ran L; Ke HZ; Cardozo CP; Bauman WA
    Osteoporos Int; 2016 Dec; 27(12):3627-3636. PubMed ID: 27436301
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Correlation between serum sclerostin level and bone density status in children on regular hemodialysis.
    Elsalam MA; El-Abden MZ; Mahmoud E; Zahab ZA; Ahmed H
    Saudi J Kidney Dis Transpl; 2019; 30(5):1022-1031. PubMed ID: 31696839
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Anti-sclerostin antibody treatment in a rat model of progressive renal osteodystrophy.
    Moe SM; Chen NX; Newman CL; Organ JM; Kneissel M; Kramer I; Gattone VH; Allen MR
    J Bone Miner Res; 2015 Mar; 30(3):499-509. PubMed ID: 25407607
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Deterioration of Cortical Bone Microarchitecture: Critical Component of Renal Osteodystrophy Evaluation.
    Sharma AK; Toussaint ND; Masterson R; Holt SG; Rajapakse CS; Ebeling PR; Mohanty ST; Baldock P; Elder GJ
    Am J Nephrol; 2018; 47(6):376-384. PubMed ID: 29791896
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Two-year cortical and trabecular bone loss in CKD-5D: biochemical and clinical predictors.
    Malluche HH; Monier-Faugere MC; Blomquist G; Davenport DL
    Osteoporos Int; 2018 Jan; 29(1):125-134. PubMed ID: 28993865
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The effect of naturally occurring chronic kidney disease on the micro-structural and mechanical properties of bone.
    Shipov A; Segev G; Meltzer H; Milrad M; Brenner O; Atkins A; Shahar R
    PLoS One; 2014; 9(10):e110057. PubMed ID: 25333360
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Chronic kidney disease bone and mineral disorder (CKD-MBD) in apolipoprotein E-deficient mice with chronic renal failure.
    Nikolov IG; Joki N; Nguyen-Khoa T; Ivanovski O; Phan O; Lacour B; Drüeke TB; Massy ZA; Dos Reis LM; Jorgetti V; Lafage-Proust MH
    Bone; 2010 Jul; 47(1):156-63. PubMed ID: 20406703
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Comprehensive Associations between Acidosis and the Skeleton in Patients with Kidney Disease.
    Levy RV; McMahon DJ; Agarwal S; Dempster D; Zhou H; Misof BM; Guo XE; Kamanda-Kosseh M; Aponte MA; Reidy K; Kumar J; Fusaro M; Brown DD; Melamed ML; Nickolas TL
    J Am Soc Nephrol; 2023 Apr; 34(4):668-681. PubMed ID: 36749125
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Sclerostin, Osteocytes, and Chronic Kidney Disease - Mineral Bone Disorder.
    Moysés RM; Schiavi SC
    Semin Dial; 2015; 28(6):578-86. PubMed ID: 26288182
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.